Evolus, Inc.
EOLS evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $528.4M
- Lead Asset:
- evolysse (Preclinical)
What it means
What to watch
Prepared research question
What matters most for EOLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EOLS
Evolus, Inc. is a global performance beauty company focused on building an aesthetic portfolio of consumer brands, including the neurotoxin Jeuveau and a new line of hyaluronic acid dermal fillers (Evolysse/Estyme) entering international markets.
Key risk: Negative equity and net loss
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$528.4M
Cash Runway
—
Lead Asset
evolysse (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 1 FDA decision for Evolus, Inc..
Evolus, Inc. is a global performance beauty company focused on building an aesthetic portfolio of consumer brands, including the neurotoxin Jeuveau and a new line of hyaluronic acid dermal fillers (Evolysse/Estyme) entering international markets.
- Cash & equivalents of $45.2M as of 2026-06-30 [sec].
- Total revenue of $84.1M as of 2026-06-30 [sec].
- Net loss of -$8.1M as of 2026-06-30 [sec].
- Shareholders' equity of -$30.9M as of 2026-06-30 [sec].
- Total debt of $160.0M as of 2026-06-30 [sec].
What works
- Evolus has launched its Estyme injectable hyaluronic acid gel collection in Europe, marking entry into the international dermal filler market [news · published 2026-05-11].
- The company believes its current capital resources, including an additional $100.0M in liquidity under the New Pharmakon Term Loans and a Revolving Credit Facility, will be sufficient for at least the next twelve months [sec_mda · as of 2026-08-05].
- Evolus has exclusive rights to commercialize five Evolysse dermal filler product candidates in the U.S. and four in Europe through a collaboration with Symatese Aesthetics S.A.S. [pipeline].
What to weigh
- Evolus reported a net loss of -$8.1M as of 2026-06-30 [sec].
- Shareholders' equity is negative at -$30.9M as of 2026-06-30 [sec].
- Total debt stands at $160.0M as of 2026-06-30, with approximately $53.0M of estimated future interest payments [sec_mda · as of 2026-08-05].
- The company used net cash of $13.5M for operating activities in the six months ended June 30, 2026, and expects to continue incurring significant expenses [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Evolus launched Estyme HA gel collection in Europe in May 2026.
“Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced "esteem"), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th”
News · May 11, 2026
Evolus has exclusive rights to commercialize Evolysse fillers in the U.S. and Europe.
“Exclusive right to commercialize and distribute five Evolysse dermal filler product candidates in the United States and four in Europe.”
As of June 30, 2026, outstanding debt was $160.0 million.
“As of June 30, 2026, our outstanding debt included $160.0 million of principal, due in 2029 and 2030, and approximately $53.0 million of estimated future interest payments”
SEC MD&A · August 5, 2026
Evolus used net cash of $13.5 million for operating activities in the first half of 2026.
“We used net cash of $13.5 million and $40.4 million for operating activities in the six months ended June 30, 2026 and 2025, respectively.”
SEC MD&A · August 5, 2026
Risks & what to watch (4)›
Key risks
- Negative equity and net loss — Shareholders' equity of -$30.9M and net loss of -$8.1M as of 2026-06-30 indicate financial strain [sec].
- High debt burden — Total debt of $160.0M with ~$53M future interest payments; debt service is a material cash requirement [sec_mda · as of 2026-08-05].
- Continued operating cash burn — Net cash used for operations was $13.5M in H1 2026; significant expenses expected to continue [sec_mda · as of 2026-08-05].
- Dependence on new product launches — Future revenue growth relies on successful commercialization of Evolysse/Estyme fillers and U.S. regulatory approvals [sec_mda · as of 2026-08-05].
What to watch
- U.S. regulatory approvals for Evolysse Sculpt and Evolysse Lips [sec_mda · as of 2026-08-05].
- Revenue growth from the European launch of Estyme and Evolysse fillers [news · published 2026-05-11].
- Ability to manage debt service and interest payments given $160M principal and $53M future interest [sec_mda · as of 2026-08-05].
- Cash burn rate and whether additional financing is needed beyond the next twelve months [sec_mda · as of 2026-08-05].
Sources: News · Pipeline · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Evolus, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Evolus, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$8M
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 10.2%
- Days to cover
- 9.0
- Shares short
- 6,656,973
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EOLS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Evolus, Inc.?
Evolus, Inc. is a global performance beauty company focused on building an aesthetic portfolio of consumer brands, including the neurotoxin Jeuveau and a new line of hyaluronic acid dermal fillers (Evolysse/Estyme) entering international markets.
What is Evolus, Inc.'s lead drug candidate?
Evolus, Inc.'s most advanced tracked candidate is evolysse (Preclinical) for Improvement of moderate to severe nasolabial folds facial wrinkles, mid face volume, lip fullness and infraorbital hollow correction..
Who is the CEO of Evolus, Inc.?
Mr. David Moatazedi is the chief executive officer of Evolus, Inc. (EOLS).
Where is Evolus, Inc. headquartered?
Evolus, Inc. (EOLS) is headquartered in Newport Beach, CA, United States.
What therapeutic areas does Evolus, Inc. focus on?
Evolus, Inc. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.